Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.01 CNY [3][8] Core Insights - The company is expected to achieve strong performance in 2025, with projected earnings per share (EPS) of 1.11 CNY, 1.44 CNY, and 1.85 CNY for the years 2025, 2026, and 2027 respectively [2][8] - The company reported a revenue of 2.97 billion CNY in 2024, reflecting a year-on-year growth of 33.4%, and a net profit attributable to the parent company of 342 million CNY, up 31.7% year-on-year [7] - The online channel transformation has shown positive results, with online revenue reaching 2.54 billion CNY in 2024, accounting for 86% of total revenue, and growing by 35.8% year-on-year [7] Financial Performance Summary - Revenue projections for 2025-2027 are as follows: 3.78 billion CNY in 2025, 4.67 billion CNY in 2026, and 5.66 billion CNY in 2027, with respective growth rates of 27.2%, 23.6%, and 21.3% [2][11] - The gross profit margin is expected to increase to 74.8% in 2025, with a net profit margin of 11.8% [2][11] - The company’s return on equity (ROE) is projected to rise to 12.4% in 2025 and 16.4% in 2027 [2][11] Brand and Product Performance - The main brand, Marubi, achieved a revenue of 2.06 billion CNY in 2024, growing by 31.69%, while the PL brand, Lianhuo, saw a revenue increase of 40.72% to 905 million CNY [7] - Revenue growth rates for product categories in 2024 were as follows: eye care at 61%, skincare at 22%, cleansing at 9%, and makeup at 40% [7] Market Position and Strategy - The company has successfully implemented a three-year online and offline channel strategy, which has stabilized market order and pricing systems [7] - The rebranding to "Marubi Biotechnology" signifies a strategic shift from traditional beauty products to biotechnology-based beauty solutions [7]

Investment Rating - The report upgrades the investment rating of the company to "Buy" [1] Core Views - The company continues to show strong performance with a revenue growth of 33.4% and a net profit growth of 31.7% in 2024, maintaining a growth momentum into Q1 2025 with revenue and net profit increasing by 28% and 22.1% respectively [5][10] - The dual-brand strategy is effectively driving growth, with both main brands, Marubi and Lianhuo, achieving significant revenue increases of 31.7% and 40.7% respectively in 2024 [6][10] - The company has successfully optimized its product structure and cost control, leading to a gross margin increase of 3.0 percentage points to 73.7% in 2024 [8][11] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 2.97 billion yuan and a net profit of 340 million yuan, with a proposed cash dividend of 0.5 yuan per share [5][10] - The quarterly revenue growth rates for 2024 were 38.7%, 18.6%, 25.8%, and 47.6% respectively, with net profit growth rates of 40.6%, 26.7%, 44.3%, and 20.1% [6] Brand and Product Performance - The Marubi brand generated 2.055 billion yuan in revenue, accounting for 69% of total revenue, while the Lianhuo brand contributed 905 million yuan, making up 30% of total revenue [6] - Key product lines such as eye care and skincare saw revenue growth of 60.8% and 21.6% respectively in 2024 [7] Channel Performance - Online sales accounted for 86% of total revenue in 2024, with a year-on-year growth of 35.8%, while offline sales grew by 20.8% [7] - The Marubi Tmall flagship store's GMV increased by 28%, and self-broadcasting and influencer sales on content platforms saw growth rates of 54% and 82% respectively [7] Cost and Margin Analysis - The gross margin for 2024 was 73.7%, with improvements across various product categories [8] - The company managed to reduce its expense ratio to 60.7% in 2024, with a notable decrease in management and R&D expenses [8] Future Projections - The company forecasts a net profit of 450 million yuan for 2025, with an expected EPS of 1.13 yuan, reflecting a continued growth trajectory [11][12] - The report anticipates a steady increase in revenue and net profit over the next few years, with projected growth rates of 27.7% and 32.9% for 2025 [12][11]

Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits for 2025-2027 projected at 458 million, 598 million, and 759 million RMB, representing year-on-year growth of 34%, 30%, and 27% respectively, corresponding to PE ratios of 36, 28, and 22 times [3][8]. Core Insights - The company's gross margin improved to 76.05% in Q1 2025, with a year-on-year increase of 1.44 percentage points and a quarter-on-quarter increase of 4.13 percentage points. The sales expense ratio decreased by 3.24 percentage points quarter-on-quarter to 52.17%, while the management expense ratio and R&D expense ratio saw slight reductions [3][8]. - The main brand, Marubi, continues to strengthen its market position in "eye care and wrinkle reduction," with a revenue of 2.055 billion RMB in 2024, a year-on-year increase of 31.69%, accounting for 69.24% of total revenue. The brand's flagship products have shown significant online sales growth [9][8]. - The PL brand, focusing on the base makeup segment, achieved a revenue of 905 million RMB in 2024, a year-on-year increase of 40.72%, contributing 30.51% to total revenue. Six foundation products exceeded 100 million RMB in annual GMV, indicating strong product performance [9][8]. Summary by Sections Financial Performance - The company reported a revenue of 2.226 billion RMB in 2023, with a growth rate of 28.52%. The projected revenue for 2024 is 2.970 billion RMB, with a growth rate of 33.44%. The net profit attributable to the parent company is expected to reach 342 million RMB in 2024, reflecting a growth rate of 31.69% [7][8]. - The diluted earnings per share are projected to increase from 0.647 RMB in 2023 to 1.143 RMB in 2025, with a corresponding increase in return on equity (ROE) from 7.75% in 2023 to 12.86% in 2025 [7][8]. Market Position - The report highlights the competitive landscape, noting that the main brand's growth has not met expectations due to intense online competition and slower-than-expected recovery in offline sales. However, the ongoing optimization of product structure and the deepening of the single product strategy are expected to drive future growth [3][8].

Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits for 2025-2027 projected at 458 million, 598 million, and 759 million RMB, representing year-on-year growth of 34%, 30%, and 27% respectively, corresponding to P/E ratios of 36, 28, and 22 times [3][8]. Core Insights - The company's gross margin improved to 76.05% in Q1 2025, with a year-on-year increase of 1.44 percentage points and a quarter-on-quarter increase of 4.13 percentage points. The sales expense ratio decreased by 3.24 percentage points quarter-on-quarter to 52.17%, while the management expense ratio and R&D expense ratio saw slight reductions [3][8]. - The main brand, Marubi, continues to strengthen its market position in "eye care and wrinkle reduction," with a revenue of 2.055 billion RMB in 2024, a year-on-year increase of 31.69%, accounting for 69.24% of total revenue. The brand's flagship products have shown significant online sales growth [9][8]. - The PL brand, focusing on the mass foundation market, achieved a revenue of 905 million RMB in 2024, a year-on-year increase of 40.72%, contributing 30.51% to total revenue. Six foundation products exceeded 100 million RMB in annual GMV, showcasing strong product performance [9][8]. Summary by Sections Financial Performance - The company reported a revenue of 2.226 billion RMB in 2023, with a growth rate of 28.52%. The projected revenues for 2024 and 2025 are 2.970 billion and 3.856 billion RMB, with growth rates of 33.44% and 29.85% respectively [7][11]. - The net profit attributable to the parent company for 2023 is 259 million RMB, with projections of 342 million and 458 million RMB for 2024 and 2025, reflecting growth rates of 48.93% and 31.69% [7][11]. Market Position and Strategy - The company is deepening its focus on major product strategies and online transformation, with both Marubi and PL brands showing strong momentum. The online and offline revenue for 2024 is projected at 2.541 billion and 427 million RMB, with year-on-year growth of 35.77% and 20.79% respectively [9][8]. - The report highlights the competitive landscape, noting that the main brand's growth has not met expectations due to intense online competition and slower-than-expected offline recovery [3].

公司代码：603983 公司简称：丸美生物 广东丸美生物技术股份有限公司 2024年度内部控制评价报告 广东丸美生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-003 广东丸美生物技术股份有限公司 关于第五届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 广东丸美生物技术股份有限公司（以下简称"公司"）第五届监事会第五次 会议于 2025 年 4 月 24 日（星期四）在公司会议室以现场结合通讯方式召开。会 议通知已于 2025 年 4 月 14 日以电子邮件、微信方式发出。本次会议应出席监事 3 人，实际出席监事 3 人。会议由监事会主席陈青梅主持。会议召开符合有关法 律、法规、部门规章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《公司 2024 年度监事会工作报告》 表决情况：3 票同意，0 票反对，0 票弃权。 本议案尚需公司 2024 年年度股东大会审议。 2、审议通过了《公司 2024 年度财务决算报告》 表决情况：3 票同意，0 票反对，0 票弃权。 本议案尚需公司 2024 年年度股东大会审议。 公司 2024 年年度报告 ...

第五届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 广东丸美生物技术股份有限公司（以下简称"公司"）第五届董事会第六 次会议于 2025 年 4 月 24 日在公司会议室以现场结合通讯方式召开。会议通知已 于 2025 年 4 月 14 日以电子邮件、微信方式发出。本次会议由董事长孙怀庆主持， 应出席董事 9 名，实出席董事 9 名，监事和相关高级管理人员列席了会议。本次 董事会会议的召集、召开符合《公司法》等有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定，决议内容合法有效。 二、董事会会议审议情况 1、审议通过了《公司 2024 年度总经理工作报告》 表决情况：9 票同意，0 票反对，0 票弃权。 证券代码：603983 证券简称：丸美生物 公告编号：2025-002 广东丸美生物技术股份有限公司 2、审议通过了《公司 2024 年度董事会工作报告》 表决情况：9 票同意，0 票反对，0 票弃权。 本议案尚需公司 2024 年度股东大会审议。 3、审议 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-004 本年度公司现金分红（包括中期已分配的现金红利）总额 300,750,000.00 广东丸美生物技术股份有限公司 2024年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 每股分配比例：每股派发现金红利0.50元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生 变动的，拟维持每股分配比例不变，相应调整每股分配总额，并将在相关公告中 披露。 公司不触及《上海证券交易所股票上市规则（2024年4月修订）》第9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、2024 年度利润分配方案 经华兴会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，广 东丸美生物技术股份有限公司（以下简称"公司"）母公司报表中期末未分配利 润为人民币 1,545,450,419.38 元。经董事会决议， ...

广东丸美生物技术股份有限公司 募集资金年度存放与使用情况的 专项鉴证报告 华兴专字[2025]24012360030 号 华兴会计师事务所(特殊普通合伙) 您可使用手机"扫一扫" 此码用于证明该审计报告是否由具有执业许可的会计师事 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.cov.cn） HK IN K 华兴会计师事务所(特殊普通合伙) XING CERTIFIED PUBLIC ACCOUNTANTS 省 福州市湖东路152号中山大厦B座6-9楼 电话(Tel):0591-87852574 传 真(Fax)· 0591-87840354 募集资金存放与使用情况鉴证报告 华兴专字[2025]24012360030号 广东丸美生物技术股份有限公司全体股东: 我们接受委托,对后附的广东丸美生物技术股份有限公司(以下简称丸美 生物）董事会编制的《2024年度募集资金年度存放与使用情况专项报告》（以 下简称"募集资金专项报告"）执行了鉴证工作。 一、 董事会的责任 1 6-9/F Block B.152 Hudong Road Fuzhou. Fujian. China ...

广东丸美生物技术股份有限公司 本 报 告 宙 华兴审字[2025]24012360010 号 华兴会计师事务所（特殊普通合伙） 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） 报告编码:闽2 No.7 会计师事务所(特殊普通合 IG CERTIFIED PUBLIC ACCOUNTAN 路159号中山大厦田座6-9楼 Hudong Road Fuzhou Fujian Ching 申话(Tel):0591-87852574 Ilttn- //www.fihxcna.com 牛 十 华兴审字[2025]24012360010号 广东丸美生物技术股份有限公司全体股东: 一、审计意见 我们审计了广东丸美生物技术股份有限公司(以下简称丸美生物)财务报 表,包括2024年12月31日的合并及母公司资产负债表,2024年度的合并及母公 司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及相 关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编 制,公允反映了丸美生物2024年12月31日的合并及母公司财务状况以及2024 年 ...